How Are DCTs Impacting Your Clinical Sites?

By Ed Miseta, Chief Editor, Clinical Leader

The technologies required to perform decentralized clinical trials (DCTs) and hybrid trials have been around for years. Unfortunately, many sponsor companies seemed reluctant to adopt them. That all changed in the spring of 2020 when the COVID-19 pandemic hit. Many drug developers were caught by surprise as clinics became overwhelmed with COVID patients. With the prospect of trials being delayed or canceled, DCTs and hybrid trials suddenly were the solution to keeping studies on track.